A phase I trial of the oral cyclin dependent kinase inhibitor CYC202 in patients with advanced malignancy

被引：0
|
作者：
White, JD
Cassidy, J
Twelves, C
Benson, C
Pacey, S
Judson, I
McGrath, H
Rose, F
Frenz, L
机构：
[1] Western Infirm & Associated Hosp, Beatson Oncol Ctr, Glasgow G11 6NT, Lanark, Scotland
[2] Royal Marsden Hosp, RMH, Sutton, Surrey, England
[3] Canc Res UK, London, England
[4] Cyclacel Ltd, Dundee, Scotland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3042
引用
收藏
页码：205S / 205S
页数：1
相关论文
共 50 条
  • [21] Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies
    Le Tourneau, Christophe
    Faivre, Sandrine
    Laurence, Valerie
    Delbaldo, Catherine
    Vera, Karina
    Girre, Veronique
    Chiao, Judy
    Armour, Sian
    Frame, Sheelagh
    Green, Simon R.
    Gianella-Borradori, Athos
    Dieras, Veronique
    Raymond, Eric
    EUROPEAN JOURNAL OF CANCER, 2010, 46 (18) : 3243 - 3250
  • [22] Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with fluorouracil in patients with advanced solid tumors
    Kortmansky, J
    Shah, MA
    Kaubisch, A
    Weyerbacher, A
    Yi, S
    Tong, W
    Sowers, R
    Gonen, M
    O'Reilly, E
    Kemeny, N
    Ilson, DI
    Saltz, LB
    Maki, RG
    Kelsen, DP
    Schwartz, GK
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (09) : 1875 - 1884
  • [23] Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol
    James P. Thomas
    Kendra D. Tutsch
    James F. Cleary
    Howard H. Bailey
    Rhoda Arzoomanian
    Dona Alberti
    Kris Simon
    Chris Feierabend
    Kimberly Binger
    Rebecca Marnocha
    Amy Dresen
    George Wilding
    Cancer Chemotherapy and Pharmacology, 2002, 50 : 465 - 472
  • [24] Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol
    Thomas, JP
    Tutsch, KD
    Cleary, JF
    Bailey, HH
    Arzoomanian, R
    Alberti, D
    Simon, K
    Feierabend, C
    Binger, K
    Marnocha, R
    Dresen, A
    Wilding, G
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2002, 50 (06) : 465 - 472
  • [25] Reversal of collasping glomerulopathy in mice with the cyclin-dependant kinase inhibitor CYC202.
    Nelson, PJ
    Gherardi, D
    D'Agati, VD
    Chu, THT
    Barnett, A
    Gianella-Borradori, A
    Gelman, IH
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 26A - 26A
  • [26] Phase I trial of sequential paclitaxel and cisplatin in combination with the cyclin dependent kinase inhibitor flavopiridol (flavo) in patients with advanced solid tumors.
    Schwartz, GK
    Kaubisch, A
    Saltz, L
    Ilson, D
    O'Reilly, E
    Barazzuol, J
    Endres, S
    Stoltz, M
    Tong, W
    Kelsen, DP
    Spriggs, D
    CLINICAL CANCER RESEARCH, 1999, 5 : 3754S - 3754S
  • [27] CYC202 (seliciclib or R-Roscovitine), a small molecule cyclin dependent kinase inhibitor, overcomes drug resistance via down-regulation of Mcl-1 in multiple myeloma (MM).
    Raje, NS
    Kumar, S
    Hideshima, T
    Roccaro, A
    Ishitsuka, K
    Chauhan, D
    Munshi, NC
    Green, SR
    Anderson, KC
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 568S - 568S
  • [28] Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors
    Schwartz, GK
    O'Reilly, E
    Ilson, D
    Saltz, L
    Sharma, S
    Tong, W
    Maslak, P
    Stoltz, M
    Eden, L
    Perkins, P
    Endres, S
    Barazzoul, J
    Spriggs, D
    Kelsen, D
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (08) : 2157 - 2170
  • [29] Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer
    Tan, AR
    Yang, XW
    Berman, A
    Zhai, SP
    Sparreboom, A
    Parr, AL
    Chow, C
    Brahim, JS
    Steinberg, SM
    Figg, WD
    Swain, SM
    CLINICAL CANCER RESEARCH, 2004, 10 (15) : 5038 - 5047
  • [30] Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms
    Senderowicz, AM
    Headlee, D
    Stinson, SF
    Lush, RM
    Kalil, N
    Villalba, L
    Hill, K
    Steinberg, SM
    Figg, WD
    Tompkins, A
    Arbuck, SG
    Sausville, EA
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (09) : 2986 - 2999
12345